2022
DOI: 10.1101/2022.05.02.490309
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Genetic and pharmacological reduction of CDK14 mitigates α-synuclein pathology in human neurons and in rodent models of Parkinson’s disease

Abstract: Parkinson's disease (PD) is a debilitating neurodegenerative disease characterized by the loss of midbrain dopaminergic neurons (DaNs) and the abnormal accumulation of alpha-Synuclein (a-Syn) protein. Currently, no treatment can slow nor halt neurodegeneration. Multiplications and mutations of the a-Syn gene (SNCA) cause PD-associated syndromes and animal models that overexpress a-Syn replicate several features of PD. Decreasing total a-Syn levels, therefore, is an attractive approach to slow down neurodegener… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
references
References 65 publications
0
0
0
Order By: Relevance